1583. In Vitro Activity of Imipenem/Relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa from Patients in ICUs in the Asia/Pacific region – SMART 2015-2018

BACKGROUND: Relebactam (REL) is an inhibitor of class A and C β-lactamases approved in the USA in combination with imipenem (IMI) and cilastatin for the treatment of complicated intraabdominal and urinary tract infections. Elevated antimicrobial resistance rates have been reported in ICUs. Using iso...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Lob, Sibylle, Hackel, Meredith, Chen, Wei-Ting, Khoo, Yivonne, Balwani, Kanchan, Young, Katherine, Motyl, Mary, Sahm, Daniel F
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Poster Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7778147/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.1763
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados